Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.
Identifieur interne : 000139 ( Main/Exploration ); précédent : 000138; suivant : 000140Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.
Auteurs : Nikolai Eroshenko [États-Unis] ; Taylor Gill [États-Unis] ; Marianna K. Keaveney [États-Unis] ; George M. Church [États-Unis] ; Jose M. Trevejo [États-Unis] ; Hannu Rajaniemi [États-Unis]Source :
- Nature biotechnology [ 1546-1696 ] ; 2020.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Betacoronavirus (physiologie), Facilitation dépendante des anticorps (MeSH), Glycoprotéine de spicule des coronavirus (métabolisme), Humains (MeSH), Infections à coronavirus (immunologie), Infections à coronavirus (prévention et contrôle), Infections à coronavirus (virologie), Maladies virales (immunologie), Maladies virales (virologie), Modèles animaux de maladie humaine (MeSH), Pandémies (MeSH), Pneumopathie virale (immunologie), Pneumopathie virale (virologie), Primates (MeSH), Vaccins antiviraux (immunologie), Virus du SRAS (physiologie).
- MESH :
- immunologie : Infections à coronavirus, Maladies virales, Pneumopathie virale, Vaccins antiviraux.
- métabolisme : Glycoprotéine de spicule des coronavirus.
- physiologie : Betacoronavirus, Virus du SRAS.
- prévention et contrôle : Infections à coronavirus.
- virologie : Infections à coronavirus, Maladies virales, Pneumopathie virale.
- Animaux, Facilitation dépendante des anticorps, Humains, Modèles animaux de maladie humaine, Pandémies, Primates.
English descriptors
- KwdEn :
- Animals (MeSH), Antibody-Dependent Enhancement (MeSH), Betacoronavirus (physiology), COVID-19 (MeSH), COVID-19 Vaccines (MeSH), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Coronavirus Infections (virology), Disease Models, Animal (MeSH), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (immunology), Pneumonia, Viral (virology), Primates (MeSH), SARS Virus (physiology), SARS-CoV-2 (MeSH), Spike Glycoprotein, Coronavirus (metabolism), Viral Vaccines (immunology), Virus Diseases (immunology), Virus Diseases (virology).
- MESH :
- chemical , immunology : Viral Vaccines.
- chemical , metabolism : Spike Glycoprotein, Coronavirus.
- chemical : COVID-19 Vaccines.
- immunology : Coronavirus Infections, Pneumonia, Viral, Virus Diseases.
- physiology : Betacoronavirus, SARS Virus.
- prevention & control : Coronavirus Infections.
- virology : Coronavirus Infections, Pneumonia, Viral, Virus Diseases.
- Animals, Antibody-Dependent Enhancement, COVID-19, Disease Models, Animal, Humans, Pandemics, Primates, SARS-CoV-2.
DOI: 10.1038/s41587-020-0577-1
PubMed: 32504046
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.</title><author><name sortKey="Eroshenko, Nikolai" sort="Eroshenko, Nikolai" uniqKey="Eroshenko N" first="Nikolai" last="Eroshenko">Nikolai Eroshenko</name><affiliation wicri:level="2"><nlm:affiliation>Helix Nanotechnologies, Cambridge, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helix Nanotechnologies, Cambridge, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Gill, Taylor" sort="Gill, Taylor" uniqKey="Gill T" first="Taylor" last="Gill">Taylor Gill</name><affiliation wicri:level="2"><nlm:affiliation>Helix Nanotechnologies, Cambridge, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helix Nanotechnologies, Cambridge, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Keaveney, Marianna K" sort="Keaveney, Marianna K" uniqKey="Keaveney M" first="Marianna K" last="Keaveney">Marianna K. Keaveney</name><affiliation wicri:level="2"><nlm:affiliation>Helix Nanotechnologies, Cambridge, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helix Nanotechnologies, Cambridge, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Church, George M" sort="Church, George M" uniqKey="Church G" first="George M" last="Church">George M. Church</name><affiliation wicri:level="2"><nlm:affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Genetics, Harvard Medical School, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Wyss Institute for Biologically Inspired Engineering, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Trevejo, Jose M" sort="Trevejo, Jose M" uniqKey="Trevejo J" first="Jose M" last="Trevejo">Jose M. Trevejo</name><affiliation wicri:level="2"><nlm:affiliation>SmartPharm Therapeutics, Cambridge, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>SmartPharm Therapeutics, Cambridge, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Rajaniemi, Hannu" sort="Rajaniemi, Hannu" uniqKey="Rajaniemi H" first="Hannu" last="Rajaniemi">Hannu Rajaniemi</name><affiliation wicri:level="2"><nlm:affiliation>Helix Nanotechnologies, Cambridge, MA, USA. hannu@helixnano.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helix Nanotechnologies, Cambridge, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32504046</idno><idno type="pmid">32504046</idno><idno type="doi">10.1038/s41587-020-0577-1</idno><idno type="wicri:Area/Main/Corpus">000203</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000203</idno><idno type="wicri:Area/Main/Curation">000203</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000203</idno><idno type="wicri:Area/Main/Exploration">000203</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.</title><author><name sortKey="Eroshenko, Nikolai" sort="Eroshenko, Nikolai" uniqKey="Eroshenko N" first="Nikolai" last="Eroshenko">Nikolai Eroshenko</name><affiliation wicri:level="2"><nlm:affiliation>Helix Nanotechnologies, Cambridge, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helix Nanotechnologies, Cambridge, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Gill, Taylor" sort="Gill, Taylor" uniqKey="Gill T" first="Taylor" last="Gill">Taylor Gill</name><affiliation wicri:level="2"><nlm:affiliation>Helix Nanotechnologies, Cambridge, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helix Nanotechnologies, Cambridge, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Keaveney, Marianna K" sort="Keaveney, Marianna K" uniqKey="Keaveney M" first="Marianna K" last="Keaveney">Marianna K. Keaveney</name><affiliation wicri:level="2"><nlm:affiliation>Helix Nanotechnologies, Cambridge, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helix Nanotechnologies, Cambridge, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Church, George M" sort="Church, George M" uniqKey="Church G" first="George M" last="Church">George M. Church</name><affiliation wicri:level="2"><nlm:affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Genetics, Harvard Medical School, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Wyss Institute for Biologically Inspired Engineering, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Trevejo, Jose M" sort="Trevejo, Jose M" uniqKey="Trevejo J" first="Jose M" last="Trevejo">Jose M. Trevejo</name><affiliation wicri:level="2"><nlm:affiliation>SmartPharm Therapeutics, Cambridge, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>SmartPharm Therapeutics, Cambridge, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Rajaniemi, Hannu" sort="Rajaniemi, Hannu" uniqKey="Rajaniemi H" first="Hannu" last="Rajaniemi">Hannu Rajaniemi</name><affiliation wicri:level="2"><nlm:affiliation>Helix Nanotechnologies, Cambridge, MA, USA. hannu@helixnano.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Helix Nanotechnologies, Cambridge, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><series><title level="j">Nature biotechnology</title><idno type="eISSN">1546-1696</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Antibody-Dependent Enhancement (MeSH)</term><term>Betacoronavirus (physiology)</term><term>COVID-19 (MeSH)</term><term>COVID-19 Vaccines (MeSH)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (virology)</term><term>Disease Models, Animal (MeSH)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (immunology)</term><term>Pneumonia, Viral (virology)</term><term>Primates (MeSH)</term><term>SARS Virus (physiology)</term><term>SARS-CoV-2 (MeSH)</term><term>Spike Glycoprotein, Coronavirus (metabolism)</term><term>Viral Vaccines (immunology)</term><term>Virus Diseases (immunology)</term><term>Virus Diseases (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Betacoronavirus (physiologie)</term><term>Facilitation dépendante des anticorps (MeSH)</term><term>Glycoprotéine de spicule des coronavirus (métabolisme)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (prévention et contrôle)</term><term>Infections à coronavirus (virologie)</term><term>Maladies virales (immunologie)</term><term>Maladies virales (virologie)</term><term>Modèles animaux de maladie humaine (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (immunologie)</term><term>Pneumopathie virale (virologie)</term><term>Primates (MeSH)</term><term>Vaccins antiviraux (immunologie)</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>COVID-19 Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies virales</term><term>Pneumopathie virale</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Maladies virales</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Virus Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Antibody-Dependent Enhancement</term><term>COVID-19</term><term>Disease Models, Animal</term><term>Humans</term><term>Pandemics</term><term>Primates</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Facilitation dépendante des anticorps</term><term>Humains</term><term>Modèles animaux de maladie humaine</term><term>Pandémies</term><term>Primates</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32504046</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1546-1696</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>07</Month></PubDate></JournalIssue><Title>Nature biotechnology</Title><ISOAbbreviation>Nat Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.</ArticleTitle><Pagination><MedlinePgn>789-791</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41587-020-0577-1</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eroshenko</LastName><ForeName>Nikolai</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Helix Nanotechnologies, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7400-2354</Identifier><AffiliationInfo><Affiliation>Helix Nanotechnologies, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keaveney</LastName><ForeName>Marianna K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Helix Nanotechnologies, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Church</LastName><ForeName>George M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trevejo</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>SmartPharm Therapeutics, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajaniemi</LastName><ForeName>Hannu</ForeName><Initials>H</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-4455-9861</Identifier><AffiliationInfo><Affiliation>Helix Nanotechnologies, Cambridge, MA, USA. hannu@helixnano.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Biotechnol</MedlineTA><NlmUniqueID>9604648</NlmUniqueID><ISSNLinking>1087-0156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019067" MajorTopicYN="Y">Antibody-Dependent Enhancement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011323" MajorTopicYN="N">Primates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32504046</ArticleId><ArticleId IdType="doi">10.1038/s41587-020-0577-1</ArticleId><ArticleId IdType="pii">10.1038/s41587-020-0577-1</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Eroshenko, Nikolai" sort="Eroshenko, Nikolai" uniqKey="Eroshenko N" first="Nikolai" last="Eroshenko">Nikolai Eroshenko</name></region><name sortKey="Church, George M" sort="Church, George M" uniqKey="Church G" first="George M" last="Church">George M. Church</name><name sortKey="Church, George M" sort="Church, George M" uniqKey="Church G" first="George M" last="Church">George M. Church</name><name sortKey="Gill, Taylor" sort="Gill, Taylor" uniqKey="Gill T" first="Taylor" last="Gill">Taylor Gill</name><name sortKey="Keaveney, Marianna K" sort="Keaveney, Marianna K" uniqKey="Keaveney M" first="Marianna K" last="Keaveney">Marianna K. Keaveney</name><name sortKey="Rajaniemi, Hannu" sort="Rajaniemi, Hannu" uniqKey="Rajaniemi H" first="Hannu" last="Rajaniemi">Hannu Rajaniemi</name><name sortKey="Trevejo, Jose M" sort="Trevejo, Jose M" uniqKey="Trevejo J" first="Jose M" last="Trevejo">Jose M. Trevejo</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Wicri/explor/CovidPublicV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000139 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000139 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Wicri
|area= CovidPublicV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32504046
|texte= Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32504046" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidPublicV1
| This area was generated with Dilib version V0.6.38. |  |